Yulieth Viviana Reyes Maldonado

Yulieth Viviana Reyes Maldonado

Auto-generated profile, based on publicly available information

Yulieth Viviana Reyes Maldonado

Universidad Pedagógica y Tecnológica de Colombia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2026 in RESPYN Revista Salud Pública y Nutrición
Verified
Journal Article
Open access
YMYulieth Viviana Reyes Maldonado
Yulieth Viviana Reyes Maldonado
JGJaime Gómez
Jaime Gómez
JGJaiber Yesid Alfonso Gómez
Jaiber Yesid Alfonso Gómez
STSilvia Fernanda Ortiz Torra
Silvia Fernanda Ortiz Torra
Introducción: El síndrome metabólico (MetS) incrementa significativamente el riesgo cardiovascular, pero la evidencia sobre el impacto del consumo de café en esta población es limitada. Objetivo: Evaluar la asociación entre el consumo de café y la incidencia de enfermedad cardiovascular, mortalidad cardiovascular y parámetros metabólicos en adultos con MetS. Método: Revisión sistemática y meta-análisis según PRISMA 2020 (PROSPERO CRD42024606335). Se buscaron estudios observacionales en PubMed, Scopus, Ovid y Google Scholar (2017–2024). Los desenlaces de incidencia y mortalidad se sintetizaron mediante hazard ratios (HR) y los metabólicos mediante diferencia de medias estandarizada (SMD). Se utilizó un modelo de efectos aleatorios; la heterogeneidad se evaluó con I² y el sesgo de publicación con la prueba de Egger. Resultados: Se incluyeron 19 estudios (1,149,246 participantes). El consumo moderado de café (1–3 tazas/día) se asoció con menor incidencia cardiovascular (HR = 0.89; IC95%: 0.87–0.91; I² = 0%), menor mortalidad cardiovascular (HR = 0.81; IC95%: 0.76–0.86; I² = 69.6%) y mejoría metabólica modesta (SMD = −0.16; IC95%: −0.21 a −0.11; I² = 45.6%). Se detectó posible sesgo de publicación. Conclusión: El consumo moderado de café se asocia con resultados cardiometabólicos favorables en adultos con MetS, aunque la evidencia es observacional y heterogénea.

27 December 2025 in IECCMEXICO
Verified
Journal Article
Open access
PDF file
RRRudy Alejandro Herrera Rosales
Rudy Alejandro Herrera Rosales
JEJorge Che Enseñat
Jorge Che Enseñat
MBMaria Mercedes de la Torre Bustamante
Maria Mercedes de la Torre Bustamante
JCJosé Arnulfo Perez Carrillo
José Arnulfo Perez Carrillo
ESEsteban Marrufo Sumano
Esteban Marrufo Sumano
WGWILMER RENE CUJILEMA GUILLIN
WILMER RENE CUJILEMA GUILLIN
Tumor adaptation and therapeutic resistance remain central challenges in modern oncology despite significant advances in targeted therapy and immunotherapy. Contemporary evidence indicates that resistance is not an isolated pharmacologic failure but an emergent property of evolving tumor ecosystems characterized by intratumoral heterogeneity, clonal selection, immune modulation, and tumor microenvironmental support. This review synthesizes landmark mechanistic and translational studies to construct an integrated framework linking evolutionary dynamics, signaling plasticity, immune escape, and precision oncology implementation. Across targeted therapies, resistance frequently develops through pathway reactivation, bypass signaling, and adaptive rewiring under selective pressure. In immunotherapy, resistance involves immune editing, checkpoint regulation complexity, impaired antigen presentation, and stromal-mediated immune exclusion. The tumor microenvironment further stabilizes therapy-tolerant populations through niche protection and cytokine-driven suppression. Genome-driven oncology provides a translational pathway for personalization; however, effective precision strategies must be dynamic and iterative, accounting for tumor evolution rather than relying on static baseline profiling. This integrative perspective supports improved therapeutic reasoning, multidisciplinary decision-making, and context-adapted implementation in diverse healthcare systems, including emerging oncology infrastructures in Latin America. Understanding resistance as an evolutionary and ecological phenomenon strengthens both clinical strategy design and advanced oncology education.

7 October 2025
Verified
Preprint
Open access
YMYulieth Viviana Reyes Maldonado
Yulieth Viviana Reyes Maldonado
DMDaniel Reyes Maldonado
Daniel Reyes Maldonado
JAJaime Gomez Ayala
Jaime Gomez Ayala

28 December 2025 in International Science Journal
Verified
Journal Article
Open access
PDF file
CVCésar Andrés López Valencia
César Andrés López Valencia
ZMZuleika Morales
Zuleika Morales
CLCristobal Washigton Franco Lucas
Cristobal Washigton Franco Lucas
LMLuz Melisa Moreno Mena
Luz Melisa Moreno Mena
YMYulieth Viviana Reyes Maldonado
Yulieth Viviana Reyes Maldonado
JEJorge Che Enseñat
Jorge Che Enseñat
Complex multimorbidity has become a defining feature of contemporary internal medicine, particularly within inflammatory–metabolic intersections such as dermatologic and endocrine disorders. As chronic conditions cluster in structured cardiometabolic networks, traditional disease-specific guideline approaches increasingly generate therapeutic conflict, polypharmacy, and reduced predictive accuracy in high-complexity patients. This study developed and evaluated an integrated precision decision-making framework designed to reconcile inflammatory burden, endocrine dysregulation, cardiovascular risk stratification, medication safety, and patient-centered prioritization within a unified clinical model. Multidimensional analysis demonstrated coherent cardiometabolic clustering with measurable inflammatory–metabolic overlap. As multimorbidity complexity increased, medication burden, adverse drug event risk, and guideline conflict rose progressively under traditional management approaches, while predictive discrimination declined. In contrast, the integrated precision framework showed lower conflict indices and improved predictive performance across escalating strata of complexity. Outcome prioritization analysis revealed a structured distribution balancing cardiovascular stabilization, metabolic control, inflammatory skin management, polypharmacy reduction, and quality-of-life considerations. These findings support the transition from fragmented, disease-centered optimization toward an integrated, value-based, and precision-guided model of internal medicine capable of addressing the biological and therapeutic interdependence characteristic of complex chronic disease networks.